719 results on '"Hideshima, T"'
Search Results
2. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
3. KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
4. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
5. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
6. Lenalidomide for the treatment of relapsed and refractory multiple myeloma
7. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
8. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors
9. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
10. β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome–aggresome–autophagosome–lysosome pathway
11. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
12. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells
13. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
14. The use of novel agents in the treatment of relapsed and refractory multiple myeloma
15. Ascorbic acid inhibits antitumor activity of bortezomib in vivo
16. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
17. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
18. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis
19. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma
20. A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
21. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway
22. Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo
23. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs
24. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27
25. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
26. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
27. Video-assisted thoracoscopic esophagectomy for esophageal cancer
28. Targeting angiogenesis via a c-Myc/ Hif-1 - dependent pathway in MM: V806
29. Targeting the Sp1 Transcription Factor in Multiple Myeloma: B569
30. Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma: B563
31. The Effect of Insulin-Like Growth Factor-1 in Waldenström Macroglobulinemia: B540
32. Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma: B469
33. A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma: B483
34. AT7519, a Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma via GSK3β: B457
35. Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis: B454
36. BAY 73-4506, A Novel Orally Available Multikinase Inhibitor in MM: B341
37. Targeting Myeloma Bone Disease via Activin A Inhibition: B357
38. Ciliary Proteins and Hedgehog Pathway in Multiple Myeloma: B281
39. A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease: B203
40. CAL-101: A Selective Inhibitor of PI3K p110Δ for the Treatment of Multiple Myeloma: B037
41. CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation: B026
42. Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma: A224
43. Phase I Trial of Perifosine, Lenalidomide, and Dexamethasone in Relapsed or Refractory Myeloma: A347
44. Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib: A349
45. Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma: A227
46. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells
47. Thalidomide in multiple myeloma
48. Nano-composite Si particle formation by plasma spraying for negative electrode of Li ion batteries.
49. Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma
50. Filmogenic Properties of Chitin / Chitosan
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.